NCT02443324 2024-07-31A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerEli Lilly and CompanyPhase 1 Completed175 enrolled 23 charts
NCT01326871 2024-06-25A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial CancerAltor BioSciencePhase 1/2 Completed68 enrolled 13 charts
NCT01282463 2019-09-09Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis CarcinomaEli Lilly and CompanyPhase 2 Completed148 enrolled 19 charts
NCT01353222 2017-05-25DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial CarcinomaDendreonPhase 2 Terminated142 enrolled 13 charts
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts
NCT00661609 2011-01-12A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder CancerAstraZenecaPhase 2 Completed54 enrolled 10 charts